Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

Archives of Disease in Childhood

Volumn 83, Issue 4, 2000, Pages 313-316

  Clark, Simon J ^a   Beresford, Michael W ^b   Subhedar, N V ^b   Shaw, N J ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

Author keywords

Bronchiolitis; Chronic lung disease; Epidemiology; Neonatal infections; Prematurity; Respiratory syncytial virus

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; BRONCHIOLITIS; CHILD HOSPITALIZATION; COHORT ANALYSIS; COST CONTROL; DRUG COST; HEALTH CARE COST; HIGH RISK POPULATION; HOSPITAL COST; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; UNITED KINGDOM; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; BRONCHIOLITIS, VIRAL; COHORT STUDIES; ENGLAND; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, PEDIATRIC; LENGTH OF STAY; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RISK FACTORS;

EID: 0033798887     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.83.4.313     Document Type: Article

References (8)

1. 1 Meert K, Heidemann S, Abella B, Sarnaik A. Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med 1990;18:1357-9.
2. 2 Kristensen K, Dahm T, Frederiksen PS, et al. Epidemiology of respiratory syncytial virus infection requiring hospitalisation in East Denmark. Pediatr Infect Dis J 1998;17:996-1000.
3. 3 Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
4. 4 Meert K, Heidemann S, Lieh-Lai M, Sarnaik A. Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised host. Pediatr Pulmono1989;7:167-70.
5. 5 The Impact-RSV Study Group. Palivizumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
6. 6 Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419-27.
7. 7 Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalizalion for respiratory syncytial virus among preterm infants. Pediatrics 1999;104:894-9.
8. 8 Anon. Synagis (palivizumab) launch information for NHS purchasers. Abbott Laboratories Limited. September 1999.